secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0000950170-23-062914
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx Q3 net loss $39.3M vs $92.9M prior year; cash $482.7M; CART-ddBCMA data at ASH with 22mo follow-up
--------------------------------------------------------------------------------

- Net loss narrowed to $39.3M from $92.9M in Q3 2022; collaboration revenue $15.0M from Kite license.
- Cash, equivalents and marketable securities $482.7M; company expects to fund operations into 2026.
- CART-ddBCMA Phase 1 data: median DOR, PFS and OS not reached at 22-month median follow-up; no delayed neurotoxicity.
- Upcoming ASH oral presentation on Dec 11, 2023 with new data at median 26.5-month follow-up.
- R&D expenses $43.8M (down from $83.5M) primarily due to non-cash charge for Lonza manufacturing agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000095017023062914/0000950170-23-062914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000095017023062914/aclx-20231113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer